Alaris Equity Partners Income 5 50 convertible unsecured subordinated Debentures T.AD.DB

Alternate Symbol(s): ADLRF | T.AD.DB.A | T.AD.UN

Financial Services Asset Management

Alaris Equity Partners Income Trust (the Trust) is a Canada-based private equity company. The Trust, through its subsidiaries, provides alternative financing to private companies. The Trust’s operations consist primarily of investments in private operating entities. The principal objective of the Trust is to generate stable and predictable cash flows for payment of distributions to unitholders of the Trust. The Trust offers a range of services, which include services, healthcare services, industrial services, professional services, information technology services, and construction-related services. The Company’s investments are made through a wholly owned Canadian corporation, Alaris Equity Partners Inc., and its American investments are made through, Alaris Equity Partners USA Inc. (Alaris USA) and Salaris USA Royalty Inc. (Salaris USA). The Trust also has a wholly owned subsidiary in the Netherlands, Alaris Cooperatief U.A. (Alaris Cooperatief).

TSX:AD.DB - Post by User

Alaris Equity Partners Income 5 50 convertible unsecured subordinated Debentures

<< Previous

Bullboard Posts

Next >>

Post by CanSiamCypon Mar 10, 2021 10:11am

166 Views

Post# 32761926

BUY recommendation on Stockhouse yesterday (pre QR release)

Alaris Royalty(AD-T)

March 9, 2021

Earnings come out at today's close. He'd like to see a dividend increase. It's very well priced. They just did an $85 million issue to fund 3 acquisitions/partners. AD looks very positive going forward in this economic recovery. He expects positive news in this report today. Pays a 7.8% dividend yield. AD converted from an income trust and increased the payout a little, considering taxes. The hope is that their investments will do better in the reopening and the stock will rise, though the yield may not remain this high. Longer term, AD could yield 5-6%, but he also hopes for regular increases in payout.

<< Previous

Bullboard Posts

Next >>

Revolutionizing medical imaging with nanocarbon-based contrast drugs